Our oncology research is focused on the discovery and development of targeted therapies that work against the processes cancers need to survive. We are investigating both small- and large-molecule approaches, and our internal research efforts are balanced with external collaborations across industry, academia and government. AbbVie's oncology pipeline includes multiple new molecules in clinical trials, being studied in more than 15 different cancers and tumour types, including some of the most widespread and difficult to treat cancers such as multiple myeloma and chronic lymphocytic leukaemia.